Back to search
FDAFDA · Food and drugs·Recall number D-0001-2018

Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.

Published October 11, 2017 · Recall initiated: July 12, 2017

Summary

FDA records drug Class III recall D-0001-2018, published October 11, 2017 and initiated July 12, 2017. Recalling firm: Pfizer Inc.; Status: Terminated; Reported quantity: 32,276 10 mL vials; Lot: Lot: 51275DD; Exp. 09/01/17. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Firm failed to control impurity for color change at the API stage.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pfizer Inc.
Distributor
Nationwide
Lot
Lot: 51275DD; Exp. 09/01/17
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10. recalled?

Yes. FDA published recall D-0001-2018 on October 11, 2017. Reported hazard: CGMP Deviations: Firm failed to control impurity for color change at the API stage.

What should I do if I have this product?

Voluntary: Firm initiated · Letter